Appendix 4D - Results for announcement to the market
Filed with ASX ·
6ix hasn’t read this filing yet.
Telix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- Grand Pharmaceutical Groups investment in Telix
- APAC Regulatory Progress Prostate and Kidney Cancer Imaging
- Appendix 4C and Activities Report for June 2022 Quarter
- Kevin Richardson appointed as CEO, Telix Americas
- Zircon Kidney Cancer Imaging Study completes Enrollment
Later from Telix Pharmaceuticals
- 1H 2022 - Results Presentation
- Final IPAX-1 Study Data Confirms Safety Tolerability Profile
- Telix Withdraws Marketing Application for Illuccix in Europe
- Chinese NMPA Approves TLX250 Phase III registration study
- Health Canada Approves Illuccix for Prostate Cancer Imaging
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals